Clinical trials located in

Alcorcón

Alcorcón city is located in Spain. Currently, 8 clinical trials are being conducted in this city.

Alcorcón, located in the metropolitan area of Madrid, Spain, is a city with a rich history dating back to the Neolithic era. Known for its vibrant cultural scene, it hosts the Universidad Rey Juan Carlos campus, contributing to its educational prominence. Alcorcón gained international attention in 2013 when it nearly became the site for the EuroVegas project. The city also prides itself on its green spaces, including the Parque de las Presillas and Parque Polvoranca, offering residents and visitors alike a natural retreat within the urban landscape.

  • CT-EU-00054335

    Testing safety and effects of telisotuzumab and docetaxel in Lung Cancer patients

    This study is for adults who have been treated before for a type of lung cancer called non-small cell lung cancer (NSCLC). The aim is to see if a new drug, called telisotuzumab vedotin, works better and is as safe as a common drug called docetaxel. In this study, cancer activity and any side-effects will be observed closely. The treatment will be given by a drip into a vein.The researchers will randomly decide whether each participant will get telisotuzumab vedotin or docetaxel, with an equal chance of getting either drug. While in the study, each person will have regular hospital or clinic visits to check how they are doing with tests and questionnaires.

    • Telisotuzumab Vedotin
    • Docetaxel
  • Comparing remibrutinib and teriflunomide for Multiple Sclerosis

    This study is all about comparing two treatments for relapsing multiple sclerosis (RMS)—a medicine called remibrutinib and another one called teriflunomide. Initially, researchers will do what’s known as a ‘double-blind, which means neither the participants nor the researchers know which treatment the participant takes. This part of the study will involve about 800 people and will go for up to 30 months. After this, the participants can continue the study openly taking remibrutinib for up to 5 years. The study will measure things like how often the MS relapses, changes in disability scale, amount of new lesions, changes in blood markers, walking and arm function, mood, pain, and deviations in various health parameters. There will be a lesser version trial simultaneously, with results from both pooled for analysis.

    • Teriflunomide
    • Remibrutinib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Studying povorcitinib safety and effects on nonsegmental vitiligo

    This trial studies the effectiveness and safety of povorcitinib for nonsegmental vitiligo. Participants will receive Povorcitinib or a placebo for 52 weeks. The study aims to see if Povorcitinib can significantly improve vitiligo symptoms on the face and body. It’s open to adults with a clinical diagnosis of nonsegmental vitiligo. Safety, side effects, and treatment efficacy are key focuses, aiming to advance vitiligo treatments and care.

    • povorcitinib
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine
  • The effectiveness of the drug cemiplimab in patients with cutaneous squamous cell carcinoma

    The scope of this research investigation is to study the effects of a drug, cemiplimab, given after surgery and radiation therapy in patients with a high risk of skin cancer recurrence. Cemiplimab is a type of antibody medication that targets proteins involved in cancer. It boosts the immune system to fight cancer cells more effectively. The major focus of this study is to understand if this drug can prevent the return of cutaneous squamous cell cancer post-surgery and radiation. Currently, there’s no confirmed treatment to stop high-risk cancers from coming back after surgery and radiation. Investigating cemiplimab may help us find a solution to this issue. The study involves two parts: in part 1, participants will receive either the study drug or placebo through an intravenous infusion periodically. This part includes a treatment period and follow-up session. Part 2 is optional and presents a possibility for the participant to receive the study drug if the cancer reoccurs.

    • Cemiplimab

See more clinical trials in other cities in Spain:

.